Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

D. G. Apaza Veliz; R. D. Herrera Vera; C. A. Cardenas Abarca; C. A. Oporto Gonzales; C. Aguilar Ramírez; J. L. Vega Ramírez; R. M. Urquizo Baldomero

doi:10.1063/1.4955384

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

D. G. Apaza Veliz, R. D. Herrera Vera, C. A. Cardenas Abarca, C. A. Oporto Gonzales, C. Aguilar Ramírez, J. L. Vega Ramírez, R. M. Urquizo Baldomero

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Abstract

The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

Original language	English
Title of host publication	Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015
Editors	Fernando Cristancho
Publisher	American Institute of Physics Inc.
ISBN (Electronic)	9780735414112
DOIs	https://doi.org/10.1063/1.4955384
State	Published - 7 Jul 2016
Event	11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015 - Medellin, Colombia Duration: 30 Nov 2015 → 4 Dec 2015

Publication series

Name	AIP Conference Proceedings
Volume	1753
ISSN (Print)	0094-243X
ISSN (Electronic)	1551-7616

Conference

Conference	11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015
Country/Territory	Colombia
City	Medellin
Period	30/11/15 → 4/12/15

Bibliographical note

Publisher Copyright:
© 2016 Author(s).

Keywords

Dosimetry
Hemodialysis
Iodine-131
Radioablative Therapy
Radiology Protection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1063/1.4955384

Cite this

Apaza Veliz, D. G., Herrera Vera, R. D., Cardenas Abarca, C. A., Oporto Gonzales, C. A., Aguilar Ramírez, C., Vega Ramírez, J. L., & Urquizo Baldomero, R. M. (2016). Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. In F. Cristancho (Ed.), Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015 Article 080014 (AIP Conference Proceedings; Vol. 1753). American Institute of Physics Inc.. https://doi.org/10.1063/1.4955384

Apaza Veliz, D. G. ; Herrera Vera, R. D. ; Cardenas Abarca, C. A. et al. / Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015. editor / Fernando Cristancho. American Institute of Physics Inc., 2016. (AIP Conference Proceedings).

@inproceedings{0cc9d508a8704e2b9d400ea70051f38d,

title = "Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru",

abstract = "The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.",

keywords = "Dosimetry, Hemodialysis, Iodine-131, Radioablative Therapy, Radiology Protection",

author = "{Apaza Veliz}, {D. G.} and {Herrera Vera}, {R. D.} and {Cardenas Abarca}, {C. A.} and {Oporto Gonzales}, {C. A.} and {Aguilar Ram{\'i}rez}, C. and {Vega Ram{\'i}rez}, {J. L.} and {Urquizo Baldomero}, {R. M.}",

note = "Publisher Copyright: {\textcopyright} 2016 Author(s).; 11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015 ; Conference date: 30-11-2015 Through 04-12-2015",

year = "2016",

month = jul,

day = "7",

doi = "10.1063/1.4955384",

language = "Ingl{\'e}s",

series = "AIP Conference Proceedings",

publisher = "American Institute of Physics Inc.",

editor = "Fernando Cristancho",

booktitle = "Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015",

}

Apaza Veliz, DG, Herrera Vera, RD, Cardenas Abarca, CA, Oporto Gonzales, CA, Aguilar Ramírez, C, Vega Ramírez, JL & Urquizo Baldomero, RM 2016, Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. in F Cristancho (ed.), Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015., 080014, AIP Conference Proceedings, vol. 1753, American Institute of Physics Inc., 11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015, Medellin, Colombia, 30/11/15. https://doi.org/10.1063/1.4955384

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. / Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A. et al.
Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015. ed. / Fernando Cristancho. American Institute of Physics Inc., 2016. 080014 (AIP Conference Proceedings; Vol. 1753).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

AU - Apaza Veliz, D. G.

AU - Herrera Vera, R. D.

AU - Cardenas Abarca, C. A.

AU - Oporto Gonzales, C. A.

AU - Aguilar Ramírez, C.

AU - Vega Ramírez, J. L.

AU - Urquizo Baldomero, R. M.

PY - 2016/7/7

Y1 - 2016/7/7

N2 - The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

AB - The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

KW - Dosimetry

KW - Hemodialysis

KW - Iodine-131

KW - Radioablative Therapy

KW - Radiology Protection

UR - http://www.scopus.com/inward/record.url?scp=84984559444&partnerID=8YFLogxK

U2 - 10.1063/1.4955384

DO - 10.1063/1.4955384

M3 - Contribución a la conferencia

AN - SCOPUS:84984559444

T3 - AIP Conference Proceedings

BT - Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015

A2 - Cristancho, Fernando

PB - American Institute of Physics Inc.

T2 - 11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015

Y2 - 30 November 2015 through 4 December 2015

ER -

Apaza Veliz DG, Herrera Vera RD, Cardenas Abarca CA, Oporto Gonzales CA, Aguilar Ramírez C, Vega Ramírez JL et al. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. In Cristancho F, editor, Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015. American Institute of Physics Inc. 2016. 080014. (AIP Conference Proceedings). doi: 10.1063/1.4955384

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

Abstract

Publication series

Conference

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this